Literature DB >> 11177655

The renin angiotensin system as a risk factor for coronary artery disease.

J A Farmer1, G Torre-Amione.   

Abstract

The renin angiotensin system was demonstrated to play a significant role in the genesis of hypertension and regulation of vascular tone over 100 years ago. The early investigations were subsequently expanded to implicate the renin angiotensin system in a variety of physiologic processes that may play a significant role in the initiation and progression of atherosclerosis. The renin angiotensin system modulates vascular structure and left ventricular hypertrophy via a number of trophic effects. Elevated levels of angiotensin II are associated with the generation of oxidative stress, and may thus play a significant role in the earliest phases of atherosclerosis. The role inflammation plays in atherosclerosis is amplified by the renin angiotensin system via the effects on adhesion molecules, growth factors, and chemoattractant molecules, which modulate the migration of inflammatory cells into the subendothelial space. The effects of angiotensin II, which may be at least partially genetically mediated, have been implicated in epidemiologic and clinical studies as a risk factor for the development of atherosclerosis. This review centers on the potential role that the renin angiotensin system plays as a risk factor for the development of atherosclerosis, and the role of converting enzyme inhibition or angiotensin receptor blockade as a mechanism to decrease the initiation, progression, and clinical consequences of the atherosclerotic process.

Entities:  

Mesh:

Year:  2001        PMID: 11177655     DOI: 10.1007/s11883-001-0047-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  34 in total

1.  Angiotensin induces inflammatory activation of human vascular smooth muscle cells.

Authors:  R Kranzhöfer; J Schmidt; C A Pfeiffer; S Hagl; P Libby; W Kübler
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-07       Impact factor: 8.311

2.  Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.

Authors:  G Nickenig; A T Bäumer; Y Temur; D Kebben; F Jockenhövel; M Böhm
Journal:  Circulation       Date:  1999-11-23       Impact factor: 29.690

3.  Hypertensive left ventricular remodeling and ACE-gene polymorphism.

Authors:  F Perticone; R Maio; C Cosco; R Ceravolo; S Iacopino; M Chello; P Mastroroberto; D Tramontano; P L Mattioli
Journal:  Cardiovasc Res       Date:  1999-07       Impact factor: 10.787

4.  ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension.

Authors:  T K Makris; G A Stavroulakis; U G Dafni; A E Gialeraki; P G Krespi; A N Hatzizacharias; C G Tsoukala; J S Vythoulkas; M K Kyriakidis
Journal:  Am Heart J       Date:  2000-11       Impact factor: 4.749

Review 5.  Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations.

Authors:  G B Mancini
Journal:  Clin Invest Med       Date:  2000-04       Impact factor: 0.825

6.  Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition.

Authors:  A Prasad; S Narayanan; S Husain; F Padder; M Waclawiw; N Epstein; A A Quyyumi
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

7.  The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.

Authors:  T Hayek; J Attias; R Coleman; S Brodsky; J Smith; J L Breslow; S Keidar
Journal:  Cardiovasc Res       Date:  1999-12       Impact factor: 10.787

8.  Effects of valsartan and 17 beta-estradiol on the oxidation of low-density lipoprotein in vitro.

Authors:  H Seeger; A O Mueck; T H Lippert
Journal:  Coron Artery Dis       Date:  2000-06       Impact factor: 1.439

9.  Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms.

Authors:  M Ruiz-Ortega; O Lorenzo; M Rupérez; S König; B Wittig; J Egido
Journal:  Circ Res       Date:  2000-06-23       Impact factor: 17.367

Review 10.  The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure.

Authors:  C F McTiernan; A M Feldman
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 3.955

View more
  11 in total

1.  The frail renin-angiotensin system.

Authors:  Peter M Abadir
Journal:  Clin Geriatr Med       Date:  2011-02       Impact factor: 3.076

Review 2.  [Blood pressure and the brain].

Authors:  A Hartmann; S Moskau
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

3.  Cognitive function and the emotional state of stroke patients on antihypertensive therapy.

Authors:  Yu A Starchina; V A Parfenov; I E Chazova; V E Sinitsyn; T S Pustovitova; I P Kolos; D V Ustyuzhanin
Journal:  Neurosci Behav Physiol       Date:  2007-01

Review 4.  Renin-angiotensin system and stroke.

Authors:  Simona Marcheselli; Giuseppe Micieli
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

Review 5.  Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases.

Authors:  Erin G Rosenbaugh; Krupa K Savalia; Devika S Manickam; Matthew C Zimmerman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-03       Impact factor: 3.619

Review 6.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

Review 7.  Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?

Authors:  Sean Ruland; Philip B Gorelick
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 8.  Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?

Authors:  Sean Ruland; Philip B Gorelick
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

9.  Angiotensin converting enzyme gene polymorphism is associated with severity of coronary artery disease in men with high total cholesterol levels.

Authors:  Joanna Borzyszkowska; Anna Stanislawska-Sachadyn; Marcin Wirtwein; Wojciech Sobiczewski; Dariusz Ciecwierz; Radoslaw Targonski; Marcin Gruchala; Andrzej Rynkiewicz; Janusz Limon
Journal:  J Appl Genet       Date:  2012-02-04       Impact factor: 3.240

10.  Cardiac overexpression of constitutively active Galpha q causes angiotensin II type1 receptor activation, leading to progressive heart failure and ventricular arrhythmias in transgenic mice.

Authors:  Naoko Matsushita; Toshihide Kashihara; Hisashi Shimojo; Satoshi Suzuki; Tsutomu Nakada; Yasuchika Takeishi; Ulrike Mende; Eiichi Taira; Mitsuhiko Yamada; Atsushi Sanbe; Masamichi Hirose
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.